Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Shares Shorted: Short Interest Down 87.3% in September

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant drop in short interest in September. As of September 30th, there was short interest totaling 56,158 shares, a drop of 87.3% from the September 15th total of 440,994 shares. Currently, 6.0% of the company’s stock are sold short. Based on an average trading volume of 119,021 shares, the short-interest ratio is presently 0.5 days.

Matinas Biopharma Stock Performance

Shares of MTNB stock traded up $0.04 during mid-day trading on Friday, hitting $2.87. The company’s stock had a trading volume of 35,267 shares, compared to its average volume of 141,686. The stock has a market cap of $2.81 million, a price-to-earnings ratio of -0.16 and a beta of 2.08. Matinas Biopharma has a 52-week low of $2.26 and a 52-week high of $28.95. The business has a 50-day moving average price of $3.03 and a 200 day moving average price of $6.74.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($3.15) EPS for the quarter.

About Matinas Biopharma

Matinas BioPharma, Inc is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration.

The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens.